{"id":64853,"date":"2026-05-09T15:19:48","date_gmt":"2026-05-09T07:19:48","guid":{"rendered":"https:\/\/flcube.com\/?p=64853"},"modified":"2026-05-09T15:19:48","modified_gmt":"2026-05-09T07:19:48","slug":"hengrui-pharmaceuticals-secures-nmpa-clinical-approval-for-kras-g12d-inhibitor-hrs-6093-and-multiple-combination-regimens-in-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64853","title":{"rendered":"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced it has received <strong>clinical trial approval from China&#8217;s National Medical Products Administration (NMPA)<\/strong> for <strong>HRS-6093<\/strong>, its novel oral <strong>KRAS G12D inhibitor<\/strong>, along with multiple combination regimens involving five additional proprietary compounds: <strong>SHR-9839 (sc)<\/strong>, <strong>SHR-1826<\/strong>, <strong>adebrelimab<\/strong>, <strong>SHR-8068<\/strong>, and <strong>FH-006<\/strong>. The approval enables evaluation of these combinations in <strong>advanced malignant solid tumors harboring KRAS G12D mutations<\/strong>, one of the most challenging oncogenic drivers to target therapeutically.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lead-compound-profile-hrs-6093\">Lead Compound Profile: HRS-6093<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Compound<\/strong><\/td><td>HRS-6093<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Novel, potent, and selective oral KRAS G12D inhibitor<\/td><\/tr><tr><td><strong>Target Specificity<\/strong><\/td><td>Specifically binds to KRAS G12D mutant protein<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Oral<\/td><\/tr><tr><td><strong>Therapeutic Area<\/strong><\/td><td>Advanced malignant solid tumors with KRAS G12D mutations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>KRAS G12D represents a historically &#8220;undruggable&#8221; target that has eluded therapeutic intervention for decades, making HRS-6093 a potentially transformative agent for patients with this specific mutation profile.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-combination-portfolio-details\">Combination Portfolio Details<\/h2>\n\n\n\n<p>The NMPA approval encompasses multiple strategic combination approaches:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-immunotherapy-combinations\">Immunotherapy Combinations<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HRS-6093 + adebrelimab<\/strong> (anti-PD-1 mAb, approved in China 2023) \u00b1 chemotherapy<\/li>\n\n\n\n<li><strong>HRS-6093 + adebrelimab + SHR-8068<\/strong> (anti-CTLA-4 mAb) \u00b1 bevacizumab<\/li>\n\n\n\n<li><strong>HRS-6093 + SHR-9839 (sc)<\/strong> \u00b1 adebrelimab or \u00b1 chemotherapy<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-targeted-therapy-combinations\">Targeted Therapy Combinations<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HRS-6093 + bevacizumab<\/strong> \u00b1 adebrelimab<\/li>\n\n\n\n<li><strong>HRS-6093 + SHR-1826<\/strong> (c-Met ADC) or <strong>FH-006<\/strong> \u00b1 adebrelimab<\/li>\n\n\n\n<li><strong>HRS-6093 + cetuximab<\/strong> \u00b1 chemotherapy<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-individual-compound-profiles\">Individual Compound Profiles<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SHR-9839 (sc):<\/strong> Subcutaneously injected humanized mAb blocking two key tumor signaling pathways<\/li>\n\n\n\n<li><strong>SHR-1826:<\/strong> c-Met-targeting antibody-drug conjugate (ADC) with tumor-specific internalization<\/li>\n\n\n\n<li><strong>Adebrelimab:<\/strong> Anti-PD-1 mAb approved for marketing in China (2023)<\/li>\n\n\n\n<li><strong>SHR-8068:<\/strong> Fully human anti-CTLA-4 mAb enhancing anti-tumor immune effects<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-amp-scientific-significance\">Strategic &amp; Scientific Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>KRAS G12D Market Opportunity:<\/strong> Represents approximately 10-15% of pancreatic cancers, 5-8% of colorectal cancers, and significant subsets of other solid tumors<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Demonstrates Hengrui&#8217;s integrated drug discovery capabilities across small molecules, monoclonal antibodies, and ADCs<\/li>\n\n\n\n<li><strong>Combination Strategy:<\/strong> Addresses tumor heterogeneity and resistance mechanisms through multi-modal approaches targeting complementary pathways<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Positions Hengrui among the vanguard of companies developing KRAS G12D inhibitors globally<\/li>\n\n\n\n<li><strong>Commercial Pipeline:<\/strong> Leverages existing approved assets (adebrelimab) while advancing next-generation candidates<\/li>\n<\/ul>\n\n\n\n<p>This comprehensive clinical program reflects Hengrui&#8217;s strategy of developing precision medicine approaches for genetically defined patient populations while maximizing the value of its proprietary pipeline through rational combination strategies.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and therapeutic potential. Actual results may differ due to risks including clinical trial outcomes, safety findings, regulatory decisions, and competitive dynamics in the oncology space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600276_20260509_LIIK.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260509_LIIK.\"><\/object><a id=\"wp-block-file--media-6fc4ebf5-9329-43e6-a20b-685fd5471255\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600276_20260509_LIIK.pdf\">600276_20260509_LIIK<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600276_20260509_LIIK.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6fc4ebf5-9329-43e6-a20b-685fd5471255\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received clinical trial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,29,2586,4228,18,852],"class_list":["post-64853","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-combination-therapy","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-pd-1-l1","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for HRS-6093, its novel oral KRAS G12D inhibitor, along with multiple combination regimens involving five additional proprietary compounds: SHR-9839 (sc), SHR-1826, adebrelimab, SHR-8068, and FH-006. The approval enables evaluation of these combinations in advanced malignant solid tumors harboring KRAS G12D mutations, one of the most challenging oncogenic drivers to target therapeutically.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64853\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for HRS-6093, its novel oral KRAS G12D inhibitor, along with multiple combination regimens involving five additional proprietary compounds: SHR-9839 (sc), SHR-1826, adebrelimab, SHR-8068, and FH-006. The approval enables evaluation of these combinations in advanced malignant solid tumors harboring KRAS G12D mutations, one of the most challenging oncogenic drivers to target therapeutically.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64853\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-09T07:19:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64853#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64853\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors\",\"datePublished\":\"2026-05-09T07:19:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64853\"},\"wordCount\":409,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Combination therapy\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"PD-1\\\/L1\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64853#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64853\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64853\",\"name\":\"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-09T07:19:48+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for HRS-6093, its novel oral KRAS G12D inhibitor, along with multiple combination regimens involving five additional proprietary compounds: SHR-9839 (sc), SHR-1826, adebrelimab, SHR-8068, and FH-006. The approval enables evaluation of these combinations in advanced malignant solid tumors harboring KRAS G12D mutations, one of the most challenging oncogenic drivers to target therapeutically.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64853#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64853\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64853#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for HRS-6093, its novel oral KRAS G12D inhibitor, along with multiple combination regimens involving five additional proprietary compounds: SHR-9839 (sc), SHR-1826, adebrelimab, SHR-8068, and FH-006. The approval enables evaluation of these combinations in advanced malignant solid tumors harboring KRAS G12D mutations, one of the most challenging oncogenic drivers to target therapeutically.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64853","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for HRS-6093, its novel oral KRAS G12D inhibitor, along with multiple combination regimens involving five additional proprietary compounds: SHR-9839 (sc), SHR-1826, adebrelimab, SHR-8068, and FH-006. The approval enables evaluation of these combinations in advanced malignant solid tumors harboring KRAS G12D mutations, one of the most challenging oncogenic drivers to target therapeutically.","og_url":"https:\/\/flcube.com\/?p=64853","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-09T07:19:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64853#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64853"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors","datePublished":"2026-05-09T07:19:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64853"},"wordCount":409,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","Combination therapy","Hengrui Pharmaceuticals","HKG: 1276","PD-1\/L1","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64853#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64853","url":"https:\/\/flcube.com\/?p=64853","name":"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-09T07:19:48+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for HRS-6093, its novel oral KRAS G12D inhibitor, along with multiple combination regimens involving five additional proprietary compounds: SHR-9839 (sc), SHR-1826, adebrelimab, SHR-8068, and FH-006. The approval enables evaluation of these combinations in advanced malignant solid tumors harboring KRAS G12D mutations, one of the most challenging oncogenic drivers to target therapeutically.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64853#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64853"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64853#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64853"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64853\/revisions"}],"predecessor-version":[{"id":64859,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64853\/revisions\/64859"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64853"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64853"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}